Tag Archives: vaccines

Takeda's New Vaccines Division Charts Course to Global Growth

Today’s vaccines business represents an almost perfect world for big Pharma. There is a vast landscape of unmet medical need; lots of new science; longer product life cycles, with low exposure to post-patent generic competition; greater stability in pricing and supply commitments; more cost-effective manufacturing and delivery technologies; and the reputational gains that come from […]
Posted in Global, Strategy | Also tagged , | Leave a comment

Vaccine Demand Spurs Innovation

Vaccine development is on a roll, boosted by biomedical research uncovering new molecular targets for preventives and treatments, as well as innovative techniques for enhancing vaccine potency and production. There is high demand for new vaccines to prevent deadly tropical diseases, illustrated by the recent Ebola virus outbreak, and for capacity to respond quickly to […]
Posted in R&D, Regulatory | Also tagged , | Leave a comment

Where's the Vaccine for Meningitis B?

The bacterial meningitis outbreak at Princeton University in recent weeks has raised questions about why there is no vaccine in US to prevent this deadly disease, when such a therapy is approved in Europe and Australia. The current Princeton health danger prompted the Centers for Disease Control and Prevention (CDC) to request emergency import of […]
Posted in Europe, FDA, Global, Market Access, R&D, Safety, Strategy | Also tagged , , , , , | Leave a comment

PhRMA Research and Hope Awards Gives Industry a Shot in the Arm

Vaccines–once the neglected also ran in big Pharma’s armamentarium of innovations–received top billing at PhRMA’s annual Research and Hope awards held at the Washington Newseum on September 11.  More than 200 industry executives, politicians and scientists recognized the accomplishments of three separate teams in developing and building access to  preventive vaccines.
Posted in Events, healthcare, R&D | Also tagged , , , , , , , , , , , | Leave a comment

UN Pact Scuttles Anti-Vaccine Provision

A new international agreement to reduce mercury contamination of air and water was recently adopted by 140 countries, without a proposal that threatened to limit access to vaccines in much of the world. The credit goes to public health authorities and medical experts who challenged a provision blocking production of vaccines with the preservative thimerosal, […]
Posted in Emerging Markets, FDA, Global, healthcare, Legal, Market Access, Patient Communication, Safety | Also tagged , , , , , | 2 Comments
  • Categories

  • Meta